Protein phosphatase activity is increased in a rat model of long-term β-adrenergic stimulation

被引:72
作者
Bokník, P
Fockenbrock, M
Herzig, S
Knapp, J
Linck, B
Lüss, H
Müller, FU
Müller, T
Schmitz, W
Schröder, F
Neumann, J
机构
[1] Univ Munster, Inst Pharmakol & Toxikol, D-48129 Munster, Germany
[2] Univ Cologne, Inst Pharmakol, D-50931 Cologne, Germany
[3] Hannover Med Sch, Innere Med Klin, D-30625 Hannover, Germany
关键词
heart hypertrophy; phospholamban; protein phosphorylation; protein kinases; protein phosphatases; protein phosphatase activity;
D O I
10.1007/s002100000283
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We tested the hypothesis that altered phosphorylation of Ca2+ regulatory proteins contributes to contractile anomalies in cardiac hypertrophy. Cardiac hypertrophy was induced in rats by chronic s.c. administration of isoproterenol (Iso, 2.4 mg/kg/day) via osmotic minipumps. On day 2 of Iso treatment the expression of atrial natriuretic factor was increased, time of relaxation in isolated papillary muscles shortened and protein expression of phospholamban (PLB) and sarcoplasmic reticulum Ca2+-ATPase reduced. In addition, the phosphorylation state of PLB at serine-16 and threonine-17 was decreased from (arbitrary units) 2.3+/-0.3 to 1.1+/-0.2 and from 4.1+/-0.6 to 2.1+/-0.2, respectively. This was not accompanied by altered activity of PLB-phosphorylating protein kinases (protein kinase A or Ca2+/calmodulin-dependent protein kinase II), whereas the activity of types 1 and 2A protein phosphatases (PP1 and -2A respectively) was enhanced from 1.1+/-0.08 to 1.71+/-0.13 nmol/mg/min. Iso treatment did not alter the PP1/PP2A activity ratio and 1 nmol/l okadaic acid, a concentration which completely blocks the catalytic subunit of PP2A, inhibited about 40% of total PP activity in all groups studied. These data indicate that the activity of both PP1 and PP2A were increased. All effects of Iso treatment were abolished by co-administration of propranolol (29.7 mg/kg/day). It is concluded that dephosphorylation of PLB is due to enhanced activity of PP1 and PP2A. We suggest that chronic beta-adrenergic stimulation, which occurs in human cardiac hypertrophy and failure, can lead to increased activity of PPs. This may contribute to altered contractile responses in the hypertrophied heart.
引用
收藏
页码:222 / 231
页数:10
相关论文
共 60 条
[21]   CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE-II AND CALCIUM-PHOSPHOLIPID-DEPENDENT PROTEIN-KINASE ACTIVITIES IN RAT-TISSUES ASSAYED WITH A SYNTHETIC PEPTIDE [J].
HASHIMOTO, Y ;
SODERLING, TR .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1987, 252 (02) :418-425
[22]   The gamma(1)34.5 protein of herpes simplex virus I complexes with protein phosphatase 1 alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase [J].
He, B ;
Gross, M ;
Roizman, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (03) :843-848
[23]   Effects of serine/threonine protein phosphatases on ion channels in excitable membranes [J].
Herzig, S ;
Neumann, J .
PHYSIOLOGICAL REVIEWS, 2000, 80 (01) :173-210
[24]   REVERSIBILITY OF CATECHOLAMINE-INDUCED DILATED CARDIOMYOPATHY IN A CHILD WITH A PHEOCHROMOCYTOMA [J].
IMPERATOMCGINLEY, J ;
GAUTIER, T ;
EHLERS, K ;
ZULLO, MA ;
GOLDSTEIN, DS ;
VAUGHAN, ED .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (13) :793-797
[25]   MOLECULAR-CLONING OF RAT PHOSPHOPROTEIN PHOSPHATASE-2A-BETA CDNA AND INCREASED EXPRESSIONS OF PHOSPHATASE 2A-ALPHA AND 2A-BETA IN RAT-LIVER TUMORS [J].
KITAGAWA, Y ;
SAKAI, R ;
TAHIRA, T ;
TSUDA, H ;
ITO, N ;
SUGIMURA, T ;
NAGAO, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 157 (02) :821-827
[27]   CLEAVAGE OF STRUCTURAL PROTEINS DURING ASSEMBLY OF HEAD OF BACTERIOPHAGE-T4 [J].
LAEMMLI, UK .
NATURE, 1970, 227 (5259) :680-+
[28]   Effects of cantharidin on force of contraction and phosphatase activity in nonfailing and failing human hearts [J].
Linck, B ;
Boknik, P ;
Knapp, J ;
Muller, FU ;
Neumann, J ;
Schmitz, W ;
Vahlensieck, U .
BRITISH JOURNAL OF PHARMACOLOGY, 1996, 119 (03) :545-550
[29]  
Linck B, 1998, J PHARMACOL EXP THER, V286, P531
[30]  
Linck B, 1999, FASEB J, V13, pA768